

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Grand Pharmaceutical Group Limited
遠大醫藥集團有限公司*
(Incorporated in Bermuda with limited liability)
(Stock Code: 00512)

**ANNOUNCEMENT PURSUANT TO
RULE 13.18 OF THE LISTING RULES**

This announcement is made by Grand Pharmaceutical Group Limited (the “**Company**”) pursuant to Rule 13.18 of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

FACILITY AGREEMENT

China Grand Pharmaceutical (HK) Limited (a wholly-owned subsidiary of the Company), as borrower (the “**Borrower**”), the Company and certain subsidiaries of the Company, as guarantors, and certain banks as lenders (the “**Lenders**”) have entered into a facility agreement (the “**Facility Agreement**”) for a term loan facility of HK\$1.3 billion (the “**Facility**”). The Facility has a term of 24 months from the first utilisation date of the Facility.

SPECIFIC PERFORMANCE OBLIGATIONS OF CONTROLLERS

Under the terms of the Facility Agreement, if, among other things, (1) Mr. Hu Kaijun and his spouse Ms. Zhou Tong (collectively the “**Controllers**”) jointly, in aggregate cease to beneficially own (directly or indirectly) at least 45% issued capital of the Company; or (2) any person or group of persons acting in concert becomes the beneficial owner of the Company which their voting share capital is greater than the Controllers, then the Lenders may cancel their commitment under the Facility Agreement and declare all outstanding loans, together with accrued interest, and all other amounts accrued or outstanding under the Facility Agreement immediately due and payable.

Continuing disclosure pursuant to Rule 13.21 of the Listing Rules will also be made in subsequent interim and annual reports of the Company for as long as the circumstances giving rise to the obligation under Rule 13.18 of the Listing Rules continue to exist.

By order of the Board
Grand Pharmaceutical Group Limited
Chairman
Dr. Tang Weikun

Hong Kong, 29 February 2024

As at the date of this announcement, the Board comprises four executive directors, namely, Dr. Tang Weikun, Mr. Zhou Chao, Dr. Shi Lin and Mr. Yang Guang, and three independent nonexecutive directors, namely, Ms. So Tosi Wan, Winnie, Dr. Pei Geng and Mr. Hu Yebi.

** For identification purpose only*